IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Equipment
SectorMedical
Phone207-556-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.21 billion
Profitability
Miscellaneous
Employees8,377
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
IDEXX Laboratories (NASDAQ:IDXX) Frequently Asked Questions
What is IDEXX Laboratories' stock symbol?
IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
How were IDEXX Laboratories' earnings last quarter?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings results on Thursday, August, 1st. The company reported $1.43 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.37 by $0.06. The company had revenue of $620.10 million for the quarter, compared to analysts' expectations of $627.10 million. IDEXX Laboratories had a return on equity of 765.45% and a net margin of 17.78%. IDEXX Laboratories's quarterly revenue was up 6.8% on a year-over-year basis. During the same period last year, the firm earned $1.23 earnings per share. View IDEXX Laboratories' Earnings History.
When is IDEXX Laboratories' next earnings date?
What guidance has IDEXX Laboratories issued on next quarter's earnings?
IDEXX Laboratories updated its FY19 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of $4.82-4.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.82. The company issued revenue guidance of $2, compared to the consensus revenue estimate of $2.41 billion.
What price target have analysts set for IDXX?
5 analysts have issued twelve-month price objectives for IDEXX Laboratories' shares. Their predictions range from $276.00 to $300.00. On average, they anticipate IDEXX Laboratories' share price to reach $289.80 in the next year. This suggests a possible upside of 7.2% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.
What is the consensus analysts' recommendation for IDEXX Laboratories?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.
What are Wall Street analysts saying about IDEXX Laboratories stock?
Here are some recent quotes from research analysts about IDEXX Laboratories stock:
- 1. Canaccord Genuity analysts commented, "We think IDXX is likely due for a new product launch around 2020 or so, but whether they announce it at the Analyst Day, or VMX remains to be seen. We reiterate our Buy on IDXX and raise our PT to $285, as we roll forward to our new 2021 estimates. Q2 beat on the bottom, delivered small miss on the top. Q2 Adj. EPS of $1.43 (+16% rep, +19% FXN) beat our $1.35/Street’s $1.37 and OM of 26.5% (+140bps Y/Y) beat our 25.4%E, as G&A came in $5M below us (disciplined expense management, low benefit costs and LPD cost controls). Q2 revs of $620M (+7% rep., +9% FXN) missed our $625M/Street’s $627M (see shortfall rationale below). GMs of 57.7% grew 50bps Y/Y and matched us (helped by 2-3% price increases, and mix benefits). Q2 rev. shortfall." (8/2/2019)
- 2. According to Zacks Investment Research, "IDEXX exited the first quarter on a promising note with better-than-expected earnings and revenues. Solid growth in organic revenues and a raised 2019 EPS guidance are encouraging. IDEXX witnessed strong gains in CAG Diagnostics recurring revenue and global premium instrument installed base in the quarter. The companion animal market fundamentals remain solid with tremendous global runway for growth. The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerated recurring CAG Diagnostics revenue growth. Over the past three months, IDEXX outperformed its industry. On the flip side, Henry Schein’s recent spin out animal health business raises concern. This wing has merged with IDEXX’ peer Vet First Choice posing the company tough competition. Also, moderating global reference lab revenue growth along with high dependence on third-party distributors are a few overhangs for IDEXX." (5/3/2019)
Has IDEXX Laboratories been receiving favorable news coverage?
News articles about IDXX stock have been trending positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IDEXX Laboratories earned a news impact score of 2.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for IDEXX Laboratories.
Are investors shorting IDEXX Laboratories?
IDEXX Laboratories saw a increase in short interest in the month of July. As of July 15th, there was short interest totalling 1,204,600 shares, an increase of 9.5% from the June 15th total of 1,100,300 shares. Based on an average trading volume of 400,100 shares, the short-interest ratio is presently 3.0 days. Currently, 1.4% of the company's shares are sold short. View IDEXX Laboratories' Current Options Chain.
Who are some of IDEXX Laboratories' key competitors?
Some companies that are related to IDEXX Laboratories include IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Heska (HSKA), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML) and ImmuCell (ICCC).
What other stocks do shareholders of IDEXX Laboratories own?
Who are IDEXX Laboratories' key executives?
IDEXX Laboratories' management team includes the folowing people:
- Mr. Jonathan W. Ayers, Chairman, CEO & Pres (Age 63)
- Mr. Brian P. McKeon, CFO, Exec. VP & Treasurer (Age 57)
- Ms. Jacqueline L. Studer, Corp. VP, Gen. Counsel & Corp. Sec. (Age 60)
- Mr. Giovani Twigge, Chief HR Officer & Corp. VP (Age 55)
- Mr. Jay Mazelsky, Exec. VP of Companion Animal Group (Age 58)
Who are IDEXX Laboratories' major shareholders?
IDEXX Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.74%), BlackRock Inc. (7.50%), BlackRock Inc. (7.50%), Bamco Inc. NY (4.58%), Price T Rowe Associates Inc. MD (3.69%) and Invesco Ltd. (1.71%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.
Which institutional investors are selling IDEXX Laboratories stock?
IDXX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, Prudential Financial Inc., AGF Investments Inc., Schroder Investment Management Group, AQR Capital Management LLC and Bank of Montreal Can. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.
Which institutional investors are buying IDEXX Laboratories stock?
IDXX stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Invesco Ltd., Marshall Wace North America L.P., Thoroughbred Financial Services LLC, Ardevora Asset Management LLP, Vanguard Group Inc. and Putnam Investments LLC. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.
How do I buy shares of IDEXX Laboratories?
Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IDEXX Laboratories' stock price today?
One share of IDXX stock can currently be purchased for approximately $270.44.
How big of a company is IDEXX Laboratories?
IDEXX Laboratories has a market capitalization of $23.28 billion and generates $2.21 billion in revenue each year. The company earns $377.03 million in net income (profit) each year or $4.26 on an earnings per share basis. IDEXX Laboratories employs 8,377 workers across the globe.View Additional Information About IDEXX Laboratories.
What is IDEXX Laboratories' official website?
How can I contact IDEXX Laboratories?
IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at 207-556-0300 or via email at [email protected]
MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe IDXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
